Center for Biologics Evaluation and Research (CBER)
CBER is the Center within FDA that regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.
Key Resources
- About CBER
- Meet Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research
- CBER Offices & Divisions
- CBER Vision & Mission
- International Activities
- News & Events (Biologics)
- CBER Reports
- Biologics Regulated Products
- Contacts in CBER
- Jobs at CBER
- CBER Frequently Asked Questions
- Biologics Electronic Reading Room (eFOI)
- What's New for Biologics
- Information on CBER Restructuring
- CBER Interim Strategic Plan FY 2017-2019
- Strategic Plan for Regulatory Science and Research 2012-2016
Resources For You
- Select CBER Projects and Activities
- CBER Performance Measures and Key Projects
- REGULATORY SUBMISSIONS - ELECTRONIC AND PAPER